Follow- on
biologics (FOBs) is a biological, inventor developed product that has greater
similarity to biological products that has been already approved. Both approved
biological medicines and FOBs have no clinical difference when it comes to the
safety as well as potency of the products. The application of FOBs also popular
as biosimilars in blood disorders, Oncology diseases, deficiencies in growth
hormones plus may others, exhibit the greatest market potential as a result of
dynamic patent scenario.
Wider choice
for biologic oncology treatment have now invaded markets including United
States. The arrival of biologic for cancer treatment would help drive low cost
for many of the highly –priced products in patient care. Treatments that worked
as restraint for cancer’s biological substructure have undergone drastic change
for some cancer types. The arrival of biosimilar now accounts for approximately
½ cancer medicine spending up from nearly 11 percent 10 years back reported IMS
Institute. Recently, Hetero pharmaceuticals introduced their biosimilar
medicine Rituximab in India under MABALL found effective in treating blood
cancer.
In another
incident the FDA recognised the first FOBs in the US. The regulatory body
confirmed that the medicine Zarxio can now be used for various chemotherapy
treatments. This drug aids in the production of white bloods cells in a
patient’s body. Besides this, the drug is a generic make of the Neupogen. Apart
from this absence of cost effective drug in the GHD treatment market also
signifies great opportunity, because the latest biologics popular as biobetters
is costly.
Today, FOBs
are being used to a greater extent in NHS. Similarly, NICE also comprises of
biosimilars in its new technology which is an appraisal on somatropin. Health
professionals believe that the biosimilar drugs for hormonal deficiency would
be highly accessible and become popular over the next four to five years
Biosimilars provide NHS significant cost saving, majorly as they are effective
for treating long – term medical conditions.
AlliedMarket Research has published a report titled “World
Biosimilars/Follow-on-Biologics - Market Opportunities and Forecast, 2014 –
2020.” As per the report the FOBs industry would register a growth of nearly
49.1 percent during the forecast period 2014 to 2020.
